Advertisement
UK markets close in 7 hours 4 minutes
  • FTSE 100

    8,145.59
    -37.37 (-0.46%)
     
  • FTSE 250

    21,129.38
    -60.14 (-0.28%)
     
  • AIM

    783.84
    -1.64 (-0.21%)
     
  • GBP/EUR

    1.1896
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2969
    +0.0003 (+0.02%)
     
  • Bitcoin GBP

    48,376.97
    -250.58 (-0.52%)
     
  • CMC Crypto 200

    1,311.74
    -29.22 (-2.18%)
     
  • S&P 500

    5,631.22
    +15.87 (+0.28%)
     
  • DOW

    40,211.72
    +210.82 (+0.53%)
     
  • CRUDE OIL

    81.16
    -0.75 (-0.92%)
     
  • GOLD FUTURES

    2,440.20
    +11.30 (+0.47%)
     
  • NIKKEI 225

    41,275.08
    +84.40 (+0.20%)
     
  • HANG SENG

    17,727.98
    -287.96 (-1.60%)
     
  • DAX

    18,473.78
    -117.11 (-0.63%)
     
  • CAC 40

    7,571.53
    -61.18 (-0.80%)
     

Novo Nordisk ends kidney disease trial, books $816 million impairment in Q2

FILE PHOTO: Novo Nordisk hopes to launch experimental obesity drug this decade

COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.

Novo has decided to stop its CLARION-CKD trial because it did not meet its primary endpoint of change in systolic blood pressure from baseline to week 12, the company said in a statement.

The impairment is related to ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, that Novo acquired from KBP Biosciences in October 2023, the Danish pharma giant said.

($1 = 6.9791 Danish crowns)

(Reporting by Louise Breusch Rasmussen, editing by Essi Lehto)